Oxford BioDynamics Announces Share Issuance for Directors
Oxford BioDynamics Plc (AIM: OBD), a leading biotechnology firm that specializes in precision clinical diagnostics, has recently declared the issuance of 2,742,657 new ordinary shares. These shares, priced at 1.1 pence each, are allocated to directors, PDMRs, and select senior staff as part of their remuneration packages. This move is an integral aspect of the company’s cash preservation strategy and was done at a price equal to the market closing price on the announced day.
Details of Share Allocation
The newly issued shares are fully paid and will rank equally with existing ordinary shares once they are admitted to trading. The admission of these shares is anticipated on the AIM market of the London Stock Exchange around the end of December 2024. Following this, the total issued share capital of Oxford BioDynamics will comprise 319,319,226 ordinary shares, all endowed with equal voting rights.
Impact on Shareholding Structures
This share issuance has prompted a recalibration of shareholdings among the company’s directors and PDMRs. For instance, Dr. Alexandre Akoulitchev, the Chief Scientific Officer, now commands 2.37% of the revised share capital. Meanwhile, Chief Financial Officer Paul Stockdale possesses 0.34%, and Non-Executive Chairman Matthew Wakefield holds 0.51%. Additionally, other key executives, including Dr. David Holbrook, Thomas Guiel, and Dr. Ewan Hunter, now hold 0.05%, 0.40%, and 0.23% of the issued share capital, respectively.
Continuing Financial Management Strategies
This issuance aligns with Oxford BioDynamics' strategy, which was indicating an intent to manage financial resources judiciously. The decision mirrors a previous announcement reflecting the company’s ongoing commitment to optimizing its remuneration strategies amidst current market conditions.
Focus on Precision Diagnostics
Oxford BioDynamics is dedicated to the advancement and commercialization of precision clinical diagnostic tests aimed at combating life-altering diseases. It harnesses its proprietary EpiSwitch® 3D genomics platform to develop tests that substantially improve the accuracy of diagnosing critical conditions, including prostate cancer and optimizing responses to immuno-oncology therapies.
Shareholder Notification Requirements
It is essential for shareholders to be aware that with the issuance of these shares, they must consider the total number of ordinary shares and voting rights in their calculations. This is in line with the FCA's Disclosure Guidance and Transparency Rules, which stipulate when shareholders are required to disclose their interests in the company.
Frequently Asked Questions
What is the purpose of the share issuance by Oxford BioDynamics?
The share issuance aims to enhance the remuneration of directors and staff while supporting the company's financial management strategy.
How will these new shares affect current shareholders?
New shares will alter the shareholding percentages of existing shareholders, which they should account for in their notifications of interest.
When are the new shares expected to be admitted to trading?
The shares are expected to be admitted to trading on the AIM market around the end of December 2024.
What technology does Oxford BioDynamics use for diagnostics?
The company employs the EpiSwitch® 3D genomics platform to enhance the accuracy of its diagnostic tests.
What key conditions are targeted by Oxford BioDynamics' tests?
The tests focus on life-changing diseases, particularly including prostate cancer and responses to immuno-oncology treatments.
